LMO2 and acute lymphoblastic leukemia: Treatment of T-ALL cells expressing LMO2, from chromosomal translocations or other promoter alterations, with these degraders showed rapid targeted protein degradation of the LMO2 transcription factor but also levels of TAL1 and E47 (members of the transcription complex; Wadman et al., 1997) are reduced.